Health

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

August 07, 2025 16:30 ET  | Source: Annexon Biosciences New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions,…

4 months ago

Extendicare Announces 2025 Second Quarter Results

MARKHAM, Ontario, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for…

5 months ago

Cannabis: The Gateway to Tomatoes? New Survey Says Yes

FORT LAUDERDALE, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis isn’t just transforming laws and lifestyles but also transforming America’s…

5 months ago

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 06, 2025 16:45 ET  | Source: Neuronetics MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),…

5 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

August 05, 2025 20:17 ET  | Source: BriaCell Therapeutics Corp. PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE)…

5 months ago

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin…

5 months ago

Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio Connected Care Platform

HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to…

5 months ago

CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them

Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune…

5 months ago

Tensive appointsmedical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market

Has more than 30 years of experience bringing innovations to market, including one of the world’s first drug-eluting coronary stents…

5 months ago

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly…

5 months ago